These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 20980752

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Rapid neurological recovery after intravenous tissue plasminogen activator in stroke: prognostic factors and outcome.
    Machumpurath B, Davis SM, Yan B.
    Cerebrovasc Dis; 2011; 31(3):278-83. PubMed ID: 21178353
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
    Power A, Epstein D, Cohen D, Bathula R, Devine J, Kar A, Taube D, Duncan N, Ames D.
    Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
    [Abstract] [Full Text] [Related]

  • 7. Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke.
    Pundik S, McWilliams-Dunnigan L, Blackham KL, Kirchner HL, Sundararajan S, Sunshine JL, Tarr RW, Selman WR, Landis DM, Suarez JI.
    J Stroke Cerebrovasc Dis; 2008 Sep; 17(5):266-72. PubMed ID: 18755405
    [Abstract] [Full Text] [Related]

  • 8. Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy.
    Masrur S, Abdullah AR, Smith EE, Hidalgo R, El-Ghandour A, Rordorf G, Schwamm LH.
    J Stroke Cerebrovasc Dis; 2011 Sep; 20(2):124-30. PubMed ID: 20598579
    [Abstract] [Full Text] [Related]

  • 9. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores.
    Wendt M, Tütüncü S, Fiebach JB, Scheitz JF, Audebert HJ, Nolte CH.
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):550-3. PubMed ID: 23433783
    [Abstract] [Full Text] [Related]

  • 10. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
    Wolfe T, Suarez JI, Tarr RW, Welter E, Landis D, Sunshine JL, Zaidat OO.
    J Stroke Cerebrovasc Dis; 2008 May; 17(3):121-8. PubMed ID: 18436152
    [Abstract] [Full Text] [Related]

  • 11. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
    Hassan AE, Zacharatos H, Hassanzadeh B, El-Gengaihy A, AlKawi A, Shhadeh A, Kirmani JF.
    J Stroke Cerebrovasc Dis; 2010 Mar; 19(2):116-20. PubMed ID: 20189087
    [Abstract] [Full Text] [Related]

  • 12. Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke.
    Miedema I, Uyttenboogaart M, Koopman K, De Keyser J, Luijckx GJ.
    Cerebrovasc Dis; 2010 Feb; 29(3):263-7. PubMed ID: 20090317
    [Abstract] [Full Text] [Related]

  • 13. Thrombolysis for acute ischemic stroke: do patients treated out of hours have a worse outcome?
    Fang K, Churilov L, Weir L, Dong Q, Davis S, Yan B.
    J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):427-32. PubMed ID: 23635920
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Post-thrombolytic hyperglycemia and 3-month outcome in acute ischemic stroke.
    Putaala J, Sairanen T, Meretoja A, Lindsberg PJ, Tiainen M, Liebkind R, Strbian D, Atula S, Artto V, Rantanen K, Silvonen P, Piironen K, Curtze S, Häppölä O, Mustanoja S, Pitkäniemi J, Salonen O, Silvennoinen H, Soinne L, Kuisma M, Tatlisumak T, Kaste M.
    Cerebrovasc Dis; 2011 Mar; 31(1):83-92. PubMed ID: 21079397
    [Abstract] [Full Text] [Related]

  • 16. Thrombolysis at 3-4.5 hours after acute ischemic stroke onset--evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry.
    Shobha N, Buchan AM, Hill MD, Canadian Alteplase for Stroke Effectiveness Study (CASES).
    Cerebrovasc Dis; 2011 Mar; 31(3):223-8. PubMed ID: 21178345
    [Abstract] [Full Text] [Related]

  • 17. Factors predicting outcome in stroke patients treated with 0.6 mg/kg alteplase: evidence from the Japan Alteplase Clinical Trial (J-ACT).
    Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Japan Alteplase Clinical Trial (J-ACT) Group.
    J Stroke Cerebrovasc Dis; 2011 Nov; 20(6):517-22. PubMed ID: 20719535
    [Abstract] [Full Text] [Related]

  • 18. Predictors of good clinical outcome in acute stroke patients treated with intravenous thrombolysis.
    Saňák D, Herzig R, Zapletalová J, Horák D, Král M, Skoloudík D, Bártková A, Veverka T, Heřman M, Kaňovský P.
    Acta Neurol Scand; 2011 May; 123(5):339-44. PubMed ID: 20597864
    [Abstract] [Full Text] [Related]

  • 19. Outcomes of Thai patients with acute ischemic stroke after intravenous thrombolysis.
    Dharmasaroja PA, Dharmasaroja P, Muengtaweepongsa S.
    J Neurol Sci; 2011 Jan 15; 300(1-2):74-7. PubMed ID: 20937509
    [Abstract] [Full Text] [Related]

  • 20. The effect of physiologic derangement in patients with stroke treated with thrombolysis.
    Idicula TT, Waje-Andreassen U, Brogger J, Naess H, Lundstadsveen MT, Thomassen L.
    J Stroke Cerebrovasc Dis; 2008 Jan 15; 17(3):141-6. PubMed ID: 18436155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.